Industry: Pharmaceuticals, Biotechnology
Androclus Therapeutics is a private clinical stage biotechnology company developing a breakthrough Epitope Specific Immunotherapy technology platform and novel therapeutics for the treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Androclus’ leading drug candidate is an orally administered peptide AT-001 (dnaJP1) for the treatment of RA. AT-001 is currently in a Phase II clinical trial that will be completed in Q3 2005. A previously completed open-label Phase I/IIa demonstrated safety, biological efficacy and trends of clinical efficacy. Androclus has partnered AT-001 with a large biotechnology ( www.androclus.com )
Androclus Therapeutics , Inc.
4275 Executive Square Suite 215
La Jolla, California 92037
USA
Tel: (858) 909-0020
Fax: (858) 909-0021